410 related articles for article (PubMed ID: 27370607)
1. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
2. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
5. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
6. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
8. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.
Madoz-Gúrpide J; Zazo S; Chamizo C; Casado V; Caramés C; Gavín E; Cristóbal I; García-Foncillas J; Rojo F
J Transl Med; 2015 Aug; 13():282. PubMed ID: 26319934
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma.
Boschert V; Klenk N; Abt A; Janaki Raman S; Fischer M; Brands RC; Seher A; Linz C; Müller-Richter UDA; Bischler T; Hartmann S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940827
[TBL] [Abstract][Full Text] [Related]
10. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
12. c-Met Signaling as a Therapeutic Target in Head and Neck Cancer.
Centuori SM; Bauman JE
Cancer J; 2022 Sep-Oct 01; 28(5):346-353. PubMed ID: 36165722
[TBL] [Abstract][Full Text] [Related]
13. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.
De Herdt MJ; Baatenburg de Jong RJ
Front Biosci; 2008 Jan; 13():2516-26. PubMed ID: 17981731
[TBL] [Abstract][Full Text] [Related]
14. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
Pollock NI; Grandis JR
Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
16. Activated HGF-c-Met Axis in Head and Neck Cancer.
Arnold L; Enders J; Thomas SM
Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29231907
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression.
Kumar D; New J; Vishwakarma V; Joshi R; Enders J; Lin F; Dasari S; Gutierrez WR; Leef G; Ponnurangam S; Chavan H; Ganaden L; Thornton MM; Dai H; Tawfik O; Straub J; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Van Houten B; Anant S; Krishnamurthy P; Thomas SM
Cancer Res; 2018 Jul; 78(14):3769-3782. PubMed ID: 29769197
[TBL] [Abstract][Full Text] [Related]
19. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas.
Galeazzi E; Olivero M; Gervasio FC; De Stefani A; Valente G; Comoglio PM; Di Renzo MF; Cortesina G
Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S138-43. PubMed ID: 9065649
[TBL] [Abstract][Full Text] [Related]
20. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
